Novartis AG - Total Cashflows From Financing Activities

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Total-Cashflows-From-Financing-Activities" stands at -19.55 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2023.

Novartis AG's third quarter result of -2.79 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 46.50 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of -2.79 Billion USD for the item "Total Cashflows From Financing Activities" represents a decrease of -630.10 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of -19.55 Billion USD for the item "Total Cashflows From Financing Activities" represents a decrease of -14.04 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -10.27 Billion United States Dollars compared to the value the year prior.
The 1 year change is -10.27 Billion United States Dollars.
The 3 year change is 0.273 Billion United States Dollars.
The 5 year change is -19.07 Billion United States Dollars.
The 10 year change is -12.40 Billion United States Dollars.

The Serie's long term average value is -10.62 Billion United States Dollars. It's latest available value, on 09/30/2025, is -8.92 Billion United States Dollars lower, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 06/30/2023, to it's latest available value, on 09/30/2025, is +2.02 Billion.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2020, to it's latest available value, on 09/30/2025, is -19.07 Billion.